$259.21-8.56 (-3.20%)
IQVIA Holdings Inc.
IQVIA Holdings Inc. in the Healthcare sector is trading at $259.21 with a market capitalization of $38.7B. Wall Street consensus targets $276.28 (18 analysts), implying a +6.6% move over the next 12 months. The stock is currently near its 52-week high of $271.80, remaining 28.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.37B↑ | $4.15B↓ | $4.36B↑ | $4.10B↑ | $4.02B |
| Gross Profit | $1.44B↑ | $1.35B↓ | $1.44B↑ | $1.37B↑ | $1.32B |
| Operating Income | $569.00M↑ | $565.00M↓ | $651.00M↑ | $573.00M↑ | $538.00M |
| Net Income | $256.00M↓ | $274.00M↓ | $514.00M↑ | $331.00M↑ | $266.00M |
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Techno...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Veeva raises its fiscal 2027 outlook as Vault CRM adoption, R&D growth and Falcon AI momentum support expanding revenue and profitability.

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

While most software companies were retreating, Paycom made an aggressive and unconventional bet on itself, and the market delivered a verdict that caught even seasoned analysts off guard.

The market is obsessed with a handful of hyperscalers, but the real story might be the thousands of customers you've never heard of.
Academic risk and quality models computed from IQV's own filings and price history, not from analyst opinion.
Mixed: 4 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z in the 1.81 to 2.99 grey zone, the band where the model gives no clear bankruptcy verdict.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, above the current 37.5% reading.
Fama-French 5-factor market beta. The five factors explain 20% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-09-08.